Relative risks of the clinical, radiographic measures at baseline, treatment modalities, and molecular markers levels influencing disease progression*
| Variables | % OA progression | Relative risk (95% CI) | p Value |
|---|---|---|---|
| *Disease progression was defined as joint space decrease ⩾0.5 mm or requirement for total hip arthroplasty at 3years (multivariate analysis). | |||
| Sex | |||
| Male | 57% (77/136) | ||
| Female | 62% (123/197) | 1.20 (0.88 to 1.63) | 0.2504 |
| Age (years) | |||
| <66 | 56% (118/211) | ||
| ⩾66 | 67% (82/122) | 1.21 (0.90 to 1.63) | 0.2099 |
| Functional impairment | |||
| <2 | 50% (56/112) | ||
| ⩾2 | 65% (144/221) | 1.52 (1.10 to 2.07) | 0.0101 |
| Joint space width (mm) | |||
| ⩾2 | 54% (114/210) | ||
| <2 | 70% (86/123) | 1.36 (1.02 to 1.82) | 0.0373 |
| Femoral head migration | |||
| Superomedial/concentric | 45% (47/105) | ||
| Lateral | 67% (153/228) | 2.34 (1.66 to 3.30) | <0.0001 |
| Treatment modalities | |||
| Placebo | 64% (113/176) | ||
| Diacerein | 55% (87/157) | 0.72 (0.54 to 0.96) | 0.0274 |
| CTX-II (ng/mmol crea) | |||
| ⩽346 | 51% (113/220) | ||
| >346 | 77% (87/113) | 2.00 (1.49 to 2.70) | <0.0001 |
| sHA (mg/ml) | |||
| ⩽137 | 54% (120/223) | ||
| >137 | 73% (80/110) | 1.69 (1.25 to 2.27) | 0.0006 |